Webinars
May 2, 2024 | 1:00 - 1:45 PM ET
Two additional sessions will be offered: May 3, 2024 | 15:00-15:45 CET – Europe/Berlin May 8, 2024 | 16:00-16:45 (UTC+8:00) – Asia/Shanghai
Generative AI (GenAI) has created an opportunity to re-think and significantly improve how we work. Although far from replacing humans, GenAI has the potential to make pharma professionals far more effective and valuable to their organizations. Join us for “Making AI Real,” a webinar series from Trinity Life Sciences dedicated to exploring how to leverage generative AI across different areas…
Sign Up Now
Webinars
May 1, 2024 | 12:00 - 12:45 PM ET / 18:00 - 18:45 CET
An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai
How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL?
As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for manufacturers aiming to achieve successful access and pricing outcomes.
In this webinar, a panel of Trinity Life Sciences’ Value, Access and Pricing experts will discuss…
Sign Up Now
Blog
Published April 8, 2024
Reliable forecast models are a cornerstone of any successful commercialization plan.
The inputs that drive those forecast models are critical.
From 2020 through 2022:
Only
1
in
10
products had performance aligned with forecasted expectations*
Nearly
60% underperformed their forecast expectations
More than
30% overperformed
Forecast models often rely on healthcare professional (HCP)-reported behavioral data.
Various subjective calibration factors are required to render the data usable, even after implementing robust market research design elements.
Data from primary market research (PMR)…
Read Now
White Papers
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they deploy it to better support their innovative medicines at launch and beyond.
Complete the form below to access the full white paper
By submitting this…
Read Now
Blog
Published April 5, 2024
Executive Summary
Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into the new Canadian Drug Agency (CDA) over the course of the next five years, as well as the implementation of time-limited reimbursement for specific drugs.
While the Canadian Drug Agency is set to advance Canada’s pharmaceutical system by standardizing…
Read Now
Blog
Published April 5, 2024
Executive Summary
“Transparency in Coverage” (TIC) data is a newer data source that has recently become available for mining unique insights in the reimbursement/economics between payers and providers. In 2020, the Federal Government TIC Rule required health insurers and group health plans, including self-funded clients, to provide cost-sharing data to consumers via machine-readable files and a consumer price transparency tool. Beginning July 1, 2022, machine-readable files were published publicly, and include pricing data for covered items and services based on…
Read Now
White Papers
Community oncology practices are critical to the delivery of cancer care in the United States, treating about 80%, of patients. (~40% in community clinics and ~40% in community hospitals).
Providing top-quality care in the community setting has unique challenges, including keeping pace with the accelerating innovation in cancer care (13 novel drugs and additional 67 indication expansions approvals in 2023 alone) while treating a widely diverse patient population, navigating increasingly complex non-clinical prescribing decision influencing factors (e.g., U.S. managed care…
Read Now
White Papers
The biopharmaceutical industry is known for its promise of life-changing innovations, but many companies continue to advance the wrong therapies into the clinic, resulting in underperformance and wasted resources. This white paper explores the concentration of activity on well-trodden ground, and the lack of focus on true innovation. With increasing global pricing pressures and policy changes, it is more important than ever to be selective about the drugs that are advanced into the market. This white paper offers insights and…
Read Now
Case Studies
Client Situation
In order to plan and efficiently utilize their sales and marketing efforts, a mid-sized biopharma client wanted to identify HCPs likely to adopt their drug in the early stage of launch
Trinity’s Role
Developed an Early Adopter Identification Engine to predict which prescribers were likely to adopt the drug in the initial launch stage
Collaborated with internal stakeholders and downstream partners for seamless execution
Created a customizable dashboard for HCP profiling, targeting prioritization and sales pattern identification
Identified…
Read Now
Webinars
May 14, 2024 | 1:00 - 1:45 PM ET
Predictive insights on stakeholder behavior are crucial, whether for demand assessments, segmentation, message testing, market mapping or ATUs—and the more rooted in reality these predictions are, the more confidence in the estimates and outputs. Join Trinity Insights experts Clive Mendonca, Managing Director & Head of Quantitative Insights and Amod Athavale, Director & Head of Integrated Insights as they lead a lively discussion of the applications and benefits of using integrated insights from PMR and real-world evidence (RWE).
Key Webinar Topics…
Sign Up Now
